BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Ringelhan M, Pfister D, O'Connor T, Pikarsky E, Heikenwalder M. The immunology of hepatocellular carcinoma. Nat Immunol. 2018;19:222-232. [PMID: 29379119 DOI: 10.1038/s41590-018-0044-z] [Cited by in Crossref: 281] [Cited by in F6Publishing: 255] [Article Influence: 93.7] [Reference Citation Analysis]
Number Citing Articles
1 Jayant K, Habib N, Huang KW, Podda M, Warwick J, Arasaradnam R. Immunological Basis of Genesis of Hepatocellular Carcinoma: Unique Challenges and Potential Opportunities through Immunomodulation. Vaccines (Basel) 2020;8:E247. [PMID: 32456200 DOI: 10.3390/vaccines8020247] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]
2 Nischalke HD, Lutz P, Bartok E, Krämer B, Langhans B, Frizler R, Berg T, Hampe J, Buch S, Datz C, Stickel F, Hartmann G, Strassburg CP, Nattermann J, Spengler U. The PNPLA3 I148M variant promotes lipid-induced hepatocyte secretion of CXC chemokines establishing a tumorigenic milieu. J Mol Med (Berl) 2019;97:1589-600. [PMID: 31637480 DOI: 10.1007/s00109-019-01836-3] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
3 Wu SF, Tseng CW, Ho YC, Chen YC, Ko PH, He YT, Tseng KC. Regulatory T Cell Function Modulated After Successful Direct-Acting Antiviral Treatment for Chronic Hepatitis C Patients. Dig Dis Sci 2020;65:1385-95. [PMID: 31559553 DOI: 10.1007/s10620-019-05850-w] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
4 Chuah S, Chew V. High-dimensional immune-profiling in cancer: implications for immunotherapy. J Immunother Cancer 2020;8:e000363. [PMID: 32034066 DOI: 10.1136/jitc-2019-000363] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 15.0] [Reference Citation Analysis]
5 Galli A, Munnia A, Cellai F, Tarocchi M, Ceni E, van Schooten FJ, Godschalk R, Giese RW, Peluso M. Ligation-Mediated Polymerase Chain Reaction Detection of 8-Oxo-7,8-Dihydro-2'-Deoxyguanosine and 5-Hydroxycytosine at the Codon 176 of the p53 Gene of Hepatitis C-Associated Hepatocellular Carcinoma Patients. Int J Mol Sci 2020;21:E6753. [PMID: 32942546 DOI: 10.3390/ijms21186753] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
6 Hack SP, Zhu AX, Wang Y. Augmenting Anticancer Immunity Through Combined Targeting of Angiogenic and PD-1/PD-L1 Pathways: Challenges and Opportunities. Front Immunol 2020;11:598877. [PMID: 33250900 DOI: 10.3389/fimmu.2020.598877] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 15.0] [Reference Citation Analysis]
7 Wu Y, Liu Z, Xu X. Molecular subtyping of hepatocellular carcinoma: A step toward precision medicine. Cancer Commun (Lond) 2020;40:681-93. [PMID: 33290597 DOI: 10.1002/cac2.12115] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 7.0] [Reference Citation Analysis]
8 Rizvi S, Wang J, El-Khoueiry AB. Liver Cancer Immunity. Hepatology 2021;73 Suppl 1:86-103. [PMID: 32516437 DOI: 10.1002/hep.31416] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 8.0] [Reference Citation Analysis]
9 Tang Y, Jiang M, Jiang HM, Ye ZJ, Huang YS, Li XS, Qin BY, Zhou RS, Pan HF, Zheng DY. The Roles of circRNAs in Liver Cancer Immunity. Front Oncol 2020;10:598464. [PMID: 33614486 DOI: 10.3389/fonc.2020.598464] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
10 Yang J, Bao Y, Chen W, Duan Y, Sun D. Nomogram Based on Systemic Immune Inflammation Index and Prognostic Nutrition Index Predicts Recurrence of Hepatocellular Carcinoma After Surgery. Front Oncol 2020;10:551668. [PMID: 33163397 DOI: 10.3389/fonc.2020.551668] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
11 Liu Z, Zhang Y, Shi C, Zhou X, Xu K, Jiao D, Sun Z, Han X. A novel immune classification reveals distinct immune escape mechanism and genomic alterations: implications for immunotherapy in hepatocellular carcinoma. J Transl Med 2021;19:5. [PMID: 33407585 DOI: 10.1186/s12967-020-02697-y] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 5.0] [Reference Citation Analysis]
12 Nawaz A, Jamal A, Arif A, Parveen Z. In vitro cytotoxic potential of Solanum nigrum against human cancer cell lines. Saudi J Biol Sci 2021;28:4786-92. [PMID: 34354467 DOI: 10.1016/j.sjbs.2021.05.004] [Reference Citation Analysis]
13 Chen S, Ma W, Cao F, Shen L, Qi H, Xie L, Wu Y, Fan W. Hepatocellular Carcinoma Within the Milan Criteria: A Novel Inflammation-Based Nomogram System to Assess the Outcomes of Ablation. Front Oncol 2020;10:1764. [PMID: 33042823 DOI: 10.3389/fonc.2020.01764] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
14 Spirk M, Zimny S, Neumann M, McMullen N, Sinal CJ, Buechler C. Chemerin-156 is the Active Isoform in Human Hepatic Stellate Cells. Int J Mol Sci 2020;21:E7555. [PMID: 33066326 DOI: 10.3390/ijms21207555] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
15 Ma J, Zhang L, Bian HR, Lu ZG, Zhu L, Yang P, Zeng ZC, Xiang ZL. A Noninvasive Prediction Nomogram for Lymph Node Metastasis of Hepatocellular Carcinoma Based on Serum Long Noncoding RNAs. Biomed Res Int 2019;2019:1710670. [PMID: 31355249 DOI: 10.1155/2019/1710670] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
16 Verboom L, Martens A, Priem D, Hoste E, Sze M, Vikkula H, Van Hove L, Voet S, Roels J, Maelfait J, Bongiovanni L, de Bruin A, Scott CL, Saeys Y, Pasparakis M, Bertrand MJM, van Loo G. OTULIN Prevents Liver Inflammation and Hepatocellular Carcinoma by Inhibiting FADD- and RIPK1 Kinase-Mediated Hepatocyte Apoptosis. Cell Rep 2020;30:2237-2247.e6. [PMID: 32075762 DOI: 10.1016/j.celrep.2020.01.028] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 9.0] [Reference Citation Analysis]
17 Anstee QM, Reeves HL, Kotsiliti E, Govaere O, Heikenwalder M. From NASH to HCC: current concepts and future challenges. Nat Rev Gastroenterol Hepatol. 2019;16:411-428. [PMID: 31028350 DOI: 10.1038/s41575-019-0145-7] [Cited by in Crossref: 268] [Cited by in F6Publishing: 241] [Article Influence: 134.0] [Reference Citation Analysis]
18 Ferrara-Romeo I, Martínez P, Blasco MA. Mice lacking RAP1 show early onset and higher rates of DEN-induced hepatocellular carcinomas in female mice. PLoS One 2018;13:e0204909. [PMID: 30307978 DOI: 10.1371/journal.pone.0204909] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
19 Nishida N. Role of Oncogenic Pathways on the Cancer Immunosuppressive Microenvironment and Its Clinical Implications in Hepatocellular Carcinoma. Cancers (Basel) 2021;13:3666. [PMID: 34359568 DOI: 10.3390/cancers13153666] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
20 Al-Rajabi R, Sun W. Immunotherapy in cholangiocarcinoma. Curr Opin Gastroenterol 2021;37:105-11. [PMID: 33507028 DOI: 10.1097/MOG.0000000000000715] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
21 Li S, Saviano A, Erstad DJ, Hoshida Y, Fuchs BC, Baumert T, Tanabe KK. Risk Factors, Pathogenesis, and Strategies for Hepatocellular Carcinoma Prevention: Emphasis on Secondary Prevention and Its Translational Challenges. J Clin Med 2020;9:E3817. [PMID: 33255794 DOI: 10.3390/jcm9123817] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
22 Li Y, He X, Zhang X, Xu Y, Wu Y, Xu X. Immune-related microRNA signature for predicting prognosis and the immune microenvironment in hepatocellular carcinoma. Life Sci 2021;265:118799. [PMID: 33220285 DOI: 10.1016/j.lfs.2020.118799] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
23 Xu Y, Kong Y, Xu J, Li X, Gou J, Yin T, He H, Zhang Y, Tang X. Doxorubicin intercalated copper diethyldithiocarbamate functionalized layered double hydroxide hybrid nanoparticles for targeted therapy of hepatocellular carcinoma. Biomater Sci 2020;8:897-911. [PMID: 31825410 DOI: 10.1039/c9bm01394f] [Cited by in Crossref: 8] [Cited by in F6Publishing: 2] [Article Influence: 4.0] [Reference Citation Analysis]
24 Nagai N, Kudo Y, Aki D, Nakagawa H, Taniguchi K. Immunomodulation by Inflammation during Liver and Gastrointestinal Tumorigenesis and Aging. Int J Mol Sci 2021;22:2238. [PMID: 33668122 DOI: 10.3390/ijms22052238] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
25 Khlaiphuengsin A, Chuaypen N, Sodsai P, Buranapraditkun S, Boonpiyathad T, Hirankarn N, Tangkijvanich P. Decreased of BAFF-R expression and B cells maturation in patients with hepatitis B virus-related hepatocellular carcinoma. World J Gastroenterol 2020;26:2645-56. [PMID: 32523317 DOI: 10.3748/wjg.v26.i20.2645] [Cited by in CrossRef: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
26 Finn RS, Ikeda M, Zhu AX, Sung MW, Baron AD, Kudo M, Okusaka T, Kobayashi M, Kumada H, Kaneko S, Pracht M, Mamontov K, Meyer T, Kubota T, Dutcus CE, Saito K, Siegel AB, Dubrovsky L, Mody K, Llovet JM. Phase Ib Study of Lenvatinib Plus Pembrolizumab in Patients With Unresectable Hepatocellular Carcinoma. J Clin Oncol 2020;38:2960-70. [PMID: 32716739 DOI: 10.1200/JCO.20.00808] [Cited by in Crossref: 100] [Cited by in F6Publishing: 70] [Article Influence: 100.0] [Reference Citation Analysis]
27 Zhang Q, He Y, Luo N, Patel SJ, Han Y, Gao R, Modak M, Carotta S, Haslinger C, Kind D, Peet GW, Zhong G, Lu S, Zhu W, Mao Y, Xiao M, Bergmann M, Hu X, Kerkar SP, Vogt AB, Pflanz S, Liu K, Peng J, Ren X, Zhang Z. Landscape and Dynamics of Single Immune Cells in Hepatocellular Carcinoma. Cell. 2019;179:829-845.e20. [PMID: 31675496 DOI: 10.1016/j.cell.2019.10.003] [Cited by in Crossref: 200] [Cited by in F6Publishing: 156] [Article Influence: 200.0] [Reference Citation Analysis]
28 Pavlović N, Kopsida M, Gerwins P, Heindryckx F. Activated platelets contribute to the progression of hepatocellular carcinoma by altering the tumor environment. Life Sci 2021;277:119612. [PMID: 33991548 DOI: 10.1016/j.lfs.2021.119612] [Reference Citation Analysis]
29 Han M, Liao Z, Liu F, Chen X, Zhang B. Modulation of the TGF-β signaling pathway by long noncoding RNA in hepatocellular carcinoma. Biomark Res 2020;8:70. [PMID: 33292618 DOI: 10.1186/s40364-020-00252-x] [Reference Citation Analysis]
30 Zhang X, Zhang J, Gao F, Fan S, Dai L, Zhang J. KPNA2-Associated Immune Analyses Highlight the Dysregulation and Prognostic Effects of GRB2, NRAS, and Their RNA-Binding Proteins in Hepatocellular Carcinoma. Front Genet 2020;11:593273. [PMID: 33193737 DOI: 10.3389/fgene.2020.593273] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
31 Zhang C, Yao R, Chen J, Zou Q, Zeng L. S100 family members: potential therapeutic target in patients with hepatocellular carcinoma: A STROBE study. Medicine (Baltimore) 2021;100:e24135. [PMID: 33546025 DOI: 10.1097/MD.0000000000024135] [Reference Citation Analysis]
32 Roderburg C, Özdirik B, Wree A, Demir M, Tacke F. Systemic treatment of hepatocellular carcinoma: from sorafenib to combination therapies. Hepat Oncol 2020;7:HEP20. [PMID: 32647565 DOI: 10.2217/hep-2020-0004] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 9.0] [Reference Citation Analysis]
33 Tong J, Ma X, Yu H, Yang J. SNHG15: a promising cancer-related long noncoding RNA. Cancer Manag Res 2019;11:5961-9. [PMID: 31308739 DOI: 10.2147/CMAR.S208054] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 7.0] [Reference Citation Analysis]
34 Taranto D, Ramirez CFA, Vegna S, de Groot MHP, de Wit N, Van Baalen M, Klarenbeek S, Akkari L. Multiparametric Analyses of Hepatocellular Carcinoma Somatic Mouse Models and Their Associated Tumor Microenvironment. Curr Protoc 2021;1:e147. [PMID: 34101385 DOI: 10.1002/cpz1.147] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
35 Koo SY, Park EJ, Lee CW. Immunological distinctions between nonalcoholic steatohepatitis and hepatocellular carcinoma. Exp Mol Med 2020;52:1209-19. [PMID: 32770081 DOI: 10.1038/s12276-020-0480-3] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 8.0] [Reference Citation Analysis]
36 Feng M, Pan Y, Kong R, Shu S. Therapy of Primary Liver Cancer. Innovation (N Y) 2020;1:100032. [PMID: 32914142 DOI: 10.1016/j.xinn.2020.100032] [Cited by in Crossref: 5] [Cited by in F6Publishing: 9] [Article Influence: 5.0] [Reference Citation Analysis]
37 Sadeghi S, Bejjani A, Finn RS. Systemic Therapy for Primary Liver Tumors: Cholangiocarcinoma and Hepatocellular Carcinoma. Surg Oncol Clin N Am 2019;28:695-715. [PMID: 31472914 DOI: 10.1016/j.soc.2019.06.015] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
38 Macek Jilkova Z, Aspord C, Decaens T. Predictive Factors for Response to PD-1/PD-L1 Checkpoint Inhibition in the Field of Hepatocellular Carcinoma: Current Status and Challenges. Cancers (Basel) 2019;11:E1554. [PMID: 31615069 DOI: 10.3390/cancers11101554] [Cited by in Crossref: 25] [Cited by in F6Publishing: 16] [Article Influence: 12.5] [Reference Citation Analysis]
39 Tovoli F, De Lorenzo S, Trevisani F. Immunotherapy with Checkpoint Inhibitors for Hepatocellular Carcinoma: Where Are We Now? Vaccines (Basel) 2020;8:E578. [PMID: 33023131 DOI: 10.3390/vaccines8040578] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 4.0] [Reference Citation Analysis]
40 Kim CG, Kim C, Yoon SE, Kim KH, Choi SJ, Kang B, Kim HR, Park SH, Shin EC, Kim YY, Kim DJ, Chung HC, Chon HJ, Choi HJ, Lim HY. Hyperprogressive disease during PD-1 blockade in patients with advanced hepatocellular carcinoma. J Hepatol. 2021;74:350-359. [PMID: 32810553 DOI: 10.1016/j.jhep.2020.08.010] [Cited by in Crossref: 20] [Cited by in F6Publishing: 22] [Article Influence: 20.0] [Reference Citation Analysis]
41 Lee HA, Goh HG, Lee YS, Jung YK, Kim JH, Yim HJ, Lee MG, An H, Jeen YT, Yeon JE, Byun KS, Seo YS. Natural killer cell activity is a risk factor for the recurrence risk after curative treatment of hepatocellular carcinoma. BMC Gastroenterol 2021;21:258. [PMID: 34118869 DOI: 10.1186/s12876-021-01833-2] [Reference Citation Analysis]
42 Rattan P, Minacapelli CD, Rustgi V. The Microbiome and Hepatocellular Carcinoma. Liver Transpl. 2020;26:1316-1327. [PMID: 32564483 DOI: 10.1002/lt.25828] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
43 Théret N, Bouezzedine F, Azar F, Diab-Assaf M, Legagneux V. ADAM and ADAMTS Proteins, New Players in the Regulation of Hepatocellular Carcinoma Microenvironment. Cancers (Basel) 2021;13:1563. [PMID: 33805340 DOI: 10.3390/cancers13071563] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
44 Yang Q, Zhang J, Xu S, Jia C, Meng W, Tang H, Zhang X, Zhang Y, Fu B. Knockdown of PHF5A Inhibits Migration and Invasion of HCC Cells via Downregulating NF-κB Signaling. Biomed Res Int 2019;2019:1621854. [PMID: 30766880 DOI: 10.1155/2019/1621854] [Cited by in Crossref: 1] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
45 Pfister D, Núñez NG, Pinyol R, Govaere O, Pinter M, Szydlowska M, Gupta R, Qiu M, Deczkowska A, Weiner A, Müller F, Sinha A, Friebel E, Engleitner T, Lenggenhager D, Moncsek A, Heide D, Stirm K, Kosla J, Kotsiliti E, Leone V, Dudek M, Yousuf S, Inverso D, Singh I, Teijeiro A, Castet F, Montironi C, Haber PK, Tiniakos D, Bedossa P, Cockell S, Younes R, Vacca M, Marra F, Schattenberg JM, Allison M, Bugianesi E, Ratziu V, Pressiani T, D'Alessio A, Personeni N, Rimassa L, Daly AK, Scheiner B, Pomej K, Kirstein MM, Vogel A, Peck-Radosavljevic M, Hucke F, Finkelmeier F, Waidmann O, Trojan J, Schulze K, Wege H, Koch S, Weinmann A, Bueter M, Rössler F, Siebenhüner A, De Dosso S, Mallm JP, Umansky V, Jugold M, Luedde T, Schietinger A, Schirmacher P, Emu B, Augustin HG, Billeter A, Müller-Stich B, Kikuchi H, Duda DG, Kütting F, Waldschmidt DT, Ebert MP, Rahbari N, Mei HE, Schulz AR, Ringelhan M, Malek N, Spahn S, Bitzer M, Ruiz de Galarreta M, Lujambio A, Dufour JF, Marron TU, Kaseb A, Kudo M, Huang YH, Djouder N, Wolter K, Zender L, Marche PN, Decaens T, Pinato DJ, Rad R, Mertens JC, Weber A, Unger K, Meissner F, Roth S, Jilkova ZM, Claassen M, Anstee QM, Amit I, Knolle P, Becher B, Llovet JM, Heikenwalder M. NASH limits anti-tumour surveillance in immunotherapy-treated HCC. Nature 2021;592:450-6. [PMID: 33762733 DOI: 10.1038/s41586-021-03362-0] [Cited by in Crossref: 41] [Cited by in F6Publishing: 26] [Article Influence: 41.0] [Reference Citation Analysis]
46 Reibe S, Febbraio MA. Relieving ER stress to target NASH-driven hepatocellular carcinoma. Nat Rev Endocrinol 2019;15:73-4. [PMID: 30552380 DOI: 10.1038/s41574-018-0145-7] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 3.5] [Reference Citation Analysis]
47 Wrighton PJ, Oderberg IM, Goessling W. There Is Something Fishy About Liver Cancer: Zebrafish Models of Hepatocellular Carcinoma. Cell Mol Gastroenterol Hepatol 2019;8:347-63. [PMID: 31108233 DOI: 10.1016/j.jcmgh.2019.05.002] [Cited by in Crossref: 17] [Cited by in F6Publishing: 14] [Article Influence: 8.5] [Reference Citation Analysis]
48 Mohs A, Kuttkat N, Otto T, Youssef SA, De Bruin A, Trautwein C. MyD88-dependent signaling in non-parenchymal cells promotes liver carcinogenesis. Carcinogenesis 2020;41:171-81. [PMID: 30770929 DOI: 10.1093/carcin/bgy173] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
49 Wang L, Wang FS. Clinical immunology and immunotherapy for hepatocellular carcinoma: current progress and challenges. Hepatol Int 2019;13:521-33. [PMID: 31352593 DOI: 10.1007/s12072-019-09967-y] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 8.5] [Reference Citation Analysis]
50 Wu X, Xue R, Peng H, Gan X, Lu X, Yan W, Tian Y, Ni X, Shen H, Cheng F, Wang X, Wang X, Lu L. Traf6 inhibitor boosts antitumor immunity by impeding regulatory T cell migration in Hepa1-6 tumor model. Int Immunopharmacol 2019;77:105965. [PMID: 31670092 DOI: 10.1016/j.intimp.2019.105965] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
51 Fan G, Tu Y, Chen C, Sun H, Wan C, Cai X. DNA methylation biomarkers for hepatocellular carcinoma. Cancer Cell Int 2018;18:140. [PMID: 30245591 DOI: 10.1186/s12935-018-0629-5] [Cited by in Crossref: 20] [Cited by in F6Publishing: 16] [Article Influence: 6.7] [Reference Citation Analysis]
52 Shi JY, Wang X, Ding GY, Dong Z, Han J, Guan Z, Ma LJ, Zheng Y, Zhang L, Yu GZ, Wang XY, Ding ZB, Ke AW, Yang H, Wang L, Ai L, Cao Y, Zhou J, Fan J, Liu X, Gao Q. Exploring prognostic indicators in the pathological images of hepatocellular carcinoma based on deep learning. Gut 2021;70:951-61. [PMID: 32998878 DOI: 10.1136/gutjnl-2020-320930] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 5.0] [Reference Citation Analysis]
53 Hsiao YW, Chiu LT, Chen CH, Shih WL, Lu TP. Tumor-Infiltrating Leukocyte Composition and Prognostic Power in Hepatitis B- and Hepatitis C-Related Hepatocellular Carcinomas. Genes (Basel) 2019;10:E630. [PMID: 31434354 DOI: 10.3390/genes10080630] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 6.0] [Reference Citation Analysis]
54 Hong GQ, Cai D, Gong JP, Lai X. Innate immune cells and their interaction with T cells in hepatocellular carcinoma. Oncol Lett 2021;21:57. [PMID: 33281968 DOI: 10.3892/ol.2020.12319] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
55 Sung PS, Jang JW. Natural Killer Cell Dysfunction in Hepatocellular Carcinoma: Pathogenesis and Clinical Implications. Int J Mol Sci. 2018;19:3648. [PMID: 30463262 DOI: 10.3390/ijms19113648] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 4.7] [Reference Citation Analysis]
56 Alipour Talesh G, Trézéguet V, Merched A. Hepatocellular Carcinoma and Statins. Biochemistry 2020;59:3393-400. [PMID: 32865979 DOI: 10.1021/acs.biochem.0c00476] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
57 Wang H, Zhang H, Wang Y, Brown ZJ, Xia Y, Huang Z, Shen C, Hu Z, Beane J, Ansa-Addo EA, Huang H, Tian D, Tsung A. Regulatory T cell and neutrophil extracellular trap interaction contributes to carcinogenesis in non-alcoholic steatohepatitis. J Hepatol 2021:S0168-8278(21)01962-0. [PMID: 34363921 DOI: 10.1016/j.jhep.2021.07.032] [Reference Citation Analysis]
58 Zhang W, Zhangyuan G, Wang F, Jin K, Shen H, Zhang L, Yuan X, Wang J, Zhang H, Yu W, Huang R, Xu X, Yin Y, Zhong G, Lin A, Sun B. The zinc finger protein Miz1 suppresses liver tumorigenesis by restricting hepatocyte-driven macrophage activation and inflammation. Immunity 2021;54:1168-1185.e8. [PMID: 34038747 DOI: 10.1016/j.immuni.2021.04.027] [Reference Citation Analysis]
59 Wei R, Zhu WW, Yu GY, Wang X, Gao C, Zhou X, Lin ZF, Shao WQ, Wang SH, Lu M, Qin LX. S100 calcium-binding protein A9 from tumor-associated macrophage enhances cancer stem cell-like properties of hepatocellular carcinoma. Int J Cancer 2021;148:1233-44. [PMID: 33205453 DOI: 10.1002/ijc.33371] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
60 Najafi Z, Sharifi M, Javadi G. LNA Inhibitor in microRNA miR-23b as a Potential Anti-proliferative Option in Human Hepatocellular Carcinoma. J Gastrointest Cancer 2020;51:109-15. [PMID: 30815771 DOI: 10.1007/s12029-019-00215-y] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
61 Busato D, Mossenta M, Baboci L, Di Cintio F, Toffoli G, Dal Bo M. Novel immunotherapeutic approaches for hepatocellular carcinoma treatment. Expert Rev Clin Pharmacol 2019;12:453-70. [PMID: 30907177 DOI: 10.1080/17512433.2019.1598859] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 7.0] [Reference Citation Analysis]
62 Sung PS, Choi MH, Yang H, Lee SK, Chun HJ, Jang JW, Choi JY, Yoon SK, Choi JI, Lee YJ, Bae SH. Diffusion-Weighted Magnetic Resonance Imaging in Hepatocellular Carcinoma as a Predictor of a Response to Cisplatin-Based Hepatic Arterial Infusion Chemotherapy. Front Oncol 2020;10:600233. [PMID: 33330098 DOI: 10.3389/fonc.2020.600233] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
63 Fang J, Wang J, Yu L, Xu W. Role of HOXC10 in Cancer. Front Oncol 2021;11:684021. [PMID: 34113572 DOI: 10.3389/fonc.2021.684021] [Reference Citation Analysis]
64 Li X, Ramadori P, Pfister D, Seehawer M, Zender L, Heikenwalder M. The immunological and metabolic landscape in primary and metastatic liver cancer. Nat Rev Cancer 2021;21:541-57. [PMID: 34326518 DOI: 10.1038/s41568-021-00383-9] [Reference Citation Analysis]
65 Peng W, Zhao J, Dong X, Banazadeh A, Huang Y, Hussien A, Mechref Y. Clinical application of quantitative glycomics. Expert Rev Proteomics 2018;15:1007-31. [PMID: 30380947 DOI: 10.1080/14789450.2018.1543594] [Cited by in Crossref: 16] [Cited by in F6Publishing: 13] [Article Influence: 5.3] [Reference Citation Analysis]
66 Wegrzyniak O, Rosestedt M, Eriksson O. Recent Progress in the Molecular Imaging of Nonalcoholic Fatty Liver Disease. Int J Mol Sci 2021;22:7348. [PMID: 34298967 DOI: 10.3390/ijms22147348] [Reference Citation Analysis]
67 Takakura K, Oikawa T, Nakano M, Saeki C, Torisu Y, Kajihara M, Saruta M. Recent Insights Into the Multiple Pathways Driving Non-alcoholic Steatohepatitis-Derived Hepatocellular Carcinoma.Front Oncol. 2019;9:762. [PMID: 31456946 DOI: 10.3389/fonc.2019.00762] [Cited by in Crossref: 12] [Cited by in F6Publishing: 15] [Article Influence: 6.0] [Reference Citation Analysis]
68 Chen J, Gingold JA, Su X. Immunomodulatory TGF-β Signaling in Hepatocellular Carcinoma. Trends Mol Med 2019;25:1010-23. [PMID: 31353124 DOI: 10.1016/j.molmed.2019.06.007] [Cited by in Crossref: 43] [Cited by in F6Publishing: 36] [Article Influence: 21.5] [Reference Citation Analysis]
69 Wu MY, Yiang GT, Cheng PW, Chu PY, Li CJ. Molecular Targets in Hepatocarcinogenesis and Implications for Therapy. J Clin Med. 2018;7. [PMID: 30104473 DOI: 10.3390/jcm7080213] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 3.7] [Reference Citation Analysis]
70 Zhai Z, Fu Q, Liu C, Zhang X, Jia P, Xia P, Liu P, Liao S, Qin T, Zhang H. Emerging Roles Of hsa-circ-0046600 Targeting The miR-640/HIF-1α Signalling Pathway In The Progression Of HCC. Onco Targets Ther 2019;12:9291-302. [PMID: 31807009 DOI: 10.2147/OTT.S229514] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 6.0] [Reference Citation Analysis]
71 Kabashima A, Shimada S, Shimokawa M, Akiyama Y, Tanabe M, Tanaka S. Molecular and immunological paradigms of hepatocellular carcinoma: Special reference to therapeutic approaches. J Hepatobiliary Pancreat Sci 2021;28:62-75. [PMID: 33259135 DOI: 10.1002/jhbp.874] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
72 Lozano-Ruiz B, González-Navajas JM. The Emerging Relevance of AIM2 in Liver Disease. Int J Mol Sci 2020;21:E6535. [PMID: 32906750 DOI: 10.3390/ijms21186535] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
73 Yan P, Zhou B, Ma Y, Wang A, Hu X, Luo Y, Yuan Y, Wei Y, Pang P, Mao J. Tracking the important role of JUNB in hepatocellular carcinoma by single-cell sequencing analysis. Oncol Lett. 2020;19:1478-1486. [PMID: 31966074 DOI: 10.3892/ol.2019.11235] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
74 De Cicco P, Ercolano G, Ianaro A. The New Era of Cancer Immunotherapy: Targeting Myeloid-Derived Suppressor Cells to Overcome Immune Evasion. Front Immunol 2020;11:1680. [PMID: 32849585 DOI: 10.3389/fimmu.2020.01680] [Cited by in Crossref: 26] [Cited by in F6Publishing: 24] [Article Influence: 26.0] [Reference Citation Analysis]
75 Zhang X, Fu X, Li T, Yan H. The prognostic value of myeloid derived suppressor cell level in hepatocellular carcinoma: A systematic review and meta-analysis. PLoS One 2019;14:e0225327. [PMID: 31790437 DOI: 10.1371/journal.pone.0225327] [Cited by in Crossref: 6] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
76 Zhu AX, Finn RS, Edeline J, Cattan S, Ogasawara S, Palmer D, Verslype C, Zagonel V, Fartoux L, Vogel A, Sarker D, Verset G, Chan SL, Knox J, Daniele B, Webber AL, Ebbinghaus SW, Ma J, Siegel AB, Cheng AL, Kudo M;  KEYNOTE-224 investigators. Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial. Lancet Oncol. 2018;19:940-952. [PMID: 29875066 DOI: 10.1016/s1470-2045(18)30351-6] [Cited by in Crossref: 742] [Cited by in F6Publishing: 456] [Article Influence: 247.3] [Reference Citation Analysis]
77 Wang L, Fan J, Ye W, Han J, Zhang Y, Zhao L, Duan J, Yin D, Yi Y. The Expression of ILT4 in Myeloid Dendritic Cells in Patients with Hepatocellular Carcinoma. Immunol Invest 2019;48:704-18. [PMID: 31044626 DOI: 10.1080/08820139.2019.1571507] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 2.5] [Reference Citation Analysis]
78 Plaz Torres MC, Lai Q, Piscaglia F, Caturelli E, Cabibbo G, Biasini E, Pelizzaro F, Marra F, Trevisani F, Giannini EG. Treatment of Hepatocellular Carcinoma with Immune Checkpoint Inhibitors and Applicability of First-Line Atezolizumab/Bevacizumab in a Real-Life Setting. J Clin Med 2021;10:3201. [PMID: 34361985 DOI: 10.3390/jcm10153201] [Reference Citation Analysis]
79 Lu M, Hartmann D, Braren R, Gupta A, Wang B, Wang Y, Mogler C, Cheng Z, Wirth T, Friess H, Kleeff J, Hüser N, Sunami Y. Oncogenic Akt-FOXO3 loop favors tumor-promoting modes and enhances oxidative damage-associated hepatocellular carcinogenesis. BMC Cancer 2019;19:887. [PMID: 31488102 DOI: 10.1186/s12885-019-6110-6] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
80 Tao P, Hong L, Tang W, Lu Q, Zhao Y, Zhang S, Ma L, Xue R. Comprehensive Characterization of Immunological Profiles and Clinical Significance in Hepatocellular Carcinoma. Front Oncol 2020;10:574778. [PMID: 33552954 DOI: 10.3389/fonc.2020.574778] [Reference Citation Analysis]
81 Jayant K, Habib N, Huang KW, Warwick J, Arasaradnam R. Recent Advances: The Imbalance of Immune Cells and Cytokines in the Pathogenesis of Hepatocellular Carcinoma. Diagnostics (Basel). 2020;10. [PMID: 32466214 DOI: 10.3390/diagnostics10050338] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
82 Zhang Z, Ma L, Goswami S, Ma J, Zheng B, Duan M, Liu L, Zhang L, Shi J, Dong L, Sun Y, Tian L, Gao Q, Zhang X. Landscape of infiltrating B cells and their clinical significance in human hepatocellular carcinoma. Oncoimmunology. 2019;8:e1571388. [PMID: 30906667 DOI: 10.1080/2162402x.2019.1571388] [Cited by in Crossref: 24] [Cited by in F6Publishing: 17] [Article Influence: 12.0] [Reference Citation Analysis]
83 Hyun J, McMahon RS, Lang AL, Edwards JS, Badilla AD, Greene ME, Stone GW, Pallikkuth S, Stevenson M, Dykxhoorn DM, Kottilil S, Pahwa S, Thomas E. HIV and HCV augments inflammatory responses through increased TREM-1 expression and signaling in Kupffer and Myeloid cells. PLoS Pathog 2019;15:e1007883. [PMID: 31260499 DOI: 10.1371/journal.ppat.1007883] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 9.0] [Reference Citation Analysis]
84 Wu YN, Zhang L, Chen T, Li X, He LH, Liu GX. Granulocyte-macrophage colony-stimulating factor protects mice against hepatocellular carcinoma by ameliorating intestinal dysbiosis and attenuating inflammation. World J Gastroenterol 2020;26:5420-36. [PMID: 33024394 DOI: 10.3748/wjg.v26.i36.5420] [Cited by in CrossRef: 1] [Article Influence: 1.0] [Reference Citation Analysis]
85 Wang Y, Zhang P, Yuan M, Li X. Overexpression of miRNA-21 Promotes the Proliferation and Invasion in Hepatocellular Carcinoma Cells via Suppressing SMAD7. Technol Cancer Res Treat 2019;18:1533033819878686. [PMID: 31554487 DOI: 10.1177/1533033819878686] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 6.0] [Reference Citation Analysis]
86 Nishida N. Metabolic disease as a risk of hepatocellular carcinoma. Clin Mol Hepatol 2021;27:87-90. [PMID: 33317238 DOI: 10.3350/cmh.2020.0302] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
87 Li F, Huangyang P, Burrows M, Guo K, Riscal R, Godfrey J, Lee KE, Lin N, Lee P, Blair IA, Keith B, Li B, Simon MC. FBP1 loss disrupts liver metabolism and promotes tumorigenesis through a hepatic stellate cell senescence secretome. Nat Cell Biol 2020;22:728-39. [PMID: 32367049 DOI: 10.1038/s41556-020-0511-2] [Cited by in Crossref: 20] [Cited by in F6Publishing: 10] [Article Influence: 20.0] [Reference Citation Analysis]
88 Wang C, He W, Yuan Y, Zhang Y, Li K, Zou R, Liao Y, Liu W, Yang Z, Zuo D, Qiu J, Zheng Y, Li B, Yuan Y. Comparison of the prognostic value of inflammation-based scores in early recurrent hepatocellular carcinoma after hepatectomy. Liver Int 2020;40:229-39. [PMID: 31652394 DOI: 10.1111/liv.14281] [Cited by in Crossref: 17] [Cited by in F6Publishing: 14] [Article Influence: 8.5] [Reference Citation Analysis]
89 Guan C, Chang Z, Gu X, Liu R. MTA2 promotes HCC progression through repressing FRMD6, a key upstream component of hippo signaling pathway. Biochem Biophys Res Commun 2019;515:112-8. [PMID: 31128910 DOI: 10.1016/j.bbrc.2019.05.025] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
90 Lin T, Zhang E, Mai PP, Zhang YZ, Chen X, Peng LS. CXCL2/10/12/14 are prognostic biomarkers and correlated with immune infiltration in hepatocellular carcinoma. Biosci Rep 2021;41:BSR20204312. [PMID: 34085699 DOI: 10.1042/BSR20204312] [Reference Citation Analysis]
91 Wu M, Xia X, Hu J, Fowlkes NW, Li S. WSX1 act as a tumor suppressor in hepatocellular carcinoma by downregulating neoplastic PD-L1 expression. Nat Commun 2021;12:3500. [PMID: 34108491 DOI: 10.1038/s41467-021-23864-9] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
92 Schwabe RF, Greten TF. Gut microbiome in HCC - Mechanisms, diagnosis and therapy. J Hepatol. 2020;72:230-238. [PMID: 31954488 DOI: 10.1016/j.jhep.2019.08.016] [Cited by in Crossref: 51] [Cited by in F6Publishing: 41] [Article Influence: 51.0] [Reference Citation Analysis]
93 Tian MX, Liu WR, Wang H, Zhou YF, Jin L, Jiang XF, Tao CY, Tang Z, Zhou PY, Fang Y, Qu WF, Ding ZB, Peng YF, Dai Z, Qiu SJ, Zhou J, Lau WY, Fan J, Shi YH. Tissue-infiltrating lymphocytes signature predicts survival in patients with early/intermediate stage hepatocellular carcinoma. BMC Med 2019;17:106. [PMID: 31164128 DOI: 10.1186/s12916-019-1341-6] [Cited by in Crossref: 14] [Cited by in F6Publishing: 10] [Article Influence: 7.0] [Reference Citation Analysis]
94 Nischalke HD, Fischer J, Klüners A, Matz-Soja M, Krämer B, Langhans B, Goeser F, Soyka M, Stickel F, Spengler U, Nattermann J, Strassburg CP, Berg T, Lutz P. A genetic variant in toll-like receptor 5 is linked to chemokine levels and hepatocellular carcinoma in steatohepatitis. Liver Int 2021;41:2139-48. [PMID: 34051061 DOI: 10.1111/liv.14980] [Reference Citation Analysis]
95 Liu F, Liu Y, Chen Z. Tim-3 expression and its role in hepatocellular carcinoma. J Hematol Oncol. 2018;11:126. [PMID: 30309387 DOI: 10.1186/s13045-018-0667-4] [Cited by in Crossref: 36] [Cited by in F6Publishing: 34] [Article Influence: 12.0] [Reference Citation Analysis]
96 Gao A, Jiang J, Xie F, Chen L. Bnip3 in mitophagy: Novel insights and potential therapeutic target for diseases of secondary mitochondrial dysfunction. Clin Chim Acta 2020;506:72-83. [PMID: 32092316 DOI: 10.1016/j.cca.2020.02.024] [Cited by in Crossref: 24] [Cited by in F6Publishing: 20] [Article Influence: 24.0] [Reference Citation Analysis]
97 Li X, Wang Y, Ye X, Liang P. Locoregional Combined With Systemic Therapies for Advanced Hepatocellular Carcinoma: An Inevitable Trend of Rapid Development. Front Mol Biosci 2021;8:635243. [PMID: 33928118 DOI: 10.3389/fmolb.2021.635243] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
98 Li H, Guo D, Zhang Y, Yang S, Zhang R. miR-664b-5p Inhibits Hepatocellular Cancer Cell Proliferation Through Targeting Oncogene AKT2. Cancer Biother Radiopharm 2020;35:605-14. [PMID: 31967930 DOI: 10.1089/cbr.2019.3043] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
99 Xi ZF, Jeong S, Wang CC, Li HJ, Guo H, Cai J, Li JX, Kong XN, Tong Y, Xia Q. Expression of IL-26 predicts prognosis of patients with hepatocellular carcinoma after surgical resection. Hepatobiliary Pancreat Dis Int 2019;18:242-8. [PMID: 30956053 DOI: 10.1016/j.hbpd.2019.03.006] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 2.5] [Reference Citation Analysis]
100 Song G, Shi Y, Zhang M, Goswami S, Afridi S, Meng L, Ma J, Chen Y, Lin Y, Zhang J, Liu Y, Jin Z, Yang S, Rao D, Zhang S, Ke A, Wang X, Cao Y, Zhou J, Fan J, Zhang X, Xi R, Gao Q. Global immune characterization of HBV/HCV-related hepatocellular carcinoma identifies macrophage and T-cell subsets associated with disease progression. Cell Discov. 2020;6:90. [PMID: 33298893 DOI: 10.1038/s41421-020-00214-5] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
101 Atanasov G, Dino K, Schierle K, Dietel C, Aust G, Pratschke J, Seehofer D, Schmelzle M, Hau HM. Angiogenic inflammation and formation of necrosis in the tumor microenvironment influence patient survival after radical surgery for de novo hepatocellular carcinoma in non-cirrhosis. World J Surg Oncol 2019;17:217. [PMID: 31830991 DOI: 10.1186/s12957-019-1756-8] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 3.5] [Reference Citation Analysis]
102 Nishida N, Kudo M. Immune checkpoint blockade for the treatment of human hepatocellular carcinoma. Hepatol Res 2018;48:622-34. [PMID: 29734514 DOI: 10.1111/hepr.13191] [Cited by in Crossref: 33] [Cited by in F6Publishing: 29] [Article Influence: 11.0] [Reference Citation Analysis]
103 Wei J, Fang D. Endoplasmic Reticulum Stress Signaling and the Pathogenesis of Hepatocarcinoma. Int J Mol Sci 2021;22:1799. [PMID: 33670323 DOI: 10.3390/ijms22041799] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
104 Ruf B, Heinrich B, Greten TF. Immunobiology and immunotherapy of HCC: spotlight on innate and innate-like immune cells. Cell Mol Immunol. 2021;18:112-127. [PMID: 33235387 DOI: 10.1038/s41423-020-00572-w] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 12.0] [Reference Citation Analysis]
105 Grohmann M, Wiede F, Dodd GT, Gurzov EN, Ooi GJ, Butt T, Rasmiena AA, Kaur S, Gulati T, Goh PK, Treloar AE, Archer S, Brown WA, Muller M, Watt MJ, Ohara O, McLean CA, Tiganis T. Obesity Drives STAT-1-Dependent NASH and STAT-3-Dependent HCC. Cell. 2018;175:1289-1306.e20. [PMID: 30454647 DOI: 10.1016/j.cell.2018.09.053] [Cited by in Crossref: 98] [Cited by in F6Publishing: 90] [Article Influence: 32.7] [Reference Citation Analysis]
106 Lindblad KE, Ruiz de Galarreta M, Lujambio A. Tumor-Intrinsic Mechanisms Regulating Immune Exclusion in Liver Cancers. Front Immunol 2021;12:642958. [PMID: 33981303 DOI: 10.3389/fimmu.2021.642958] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
107 Désert R, Nieto N, Musso O. Dimensions of hepatocellular carcinoma phenotypic diversity. World J Gastroenterol 2018;24:4536-47. [PMID: 30386103 DOI: 10.3748/wjg.v24.i40.4536] [Cited by in CrossRef: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
108 Wang J, Miao Y, Ran J, Yang Y, Guan Q, Mi D. Construction prognosis model based on autophagy-related gene signatures in hepatocellular carcinoma. Biomark Med 2020;14:1229-42. [PMID: 33021390 DOI: 10.2217/bmm-2020-0170] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
109 Bresnahan E, Ramadori P, Heikenwalder M, Zender L, Lujambio A. Novel patient-derived preclinical models of liver cancer. J Hepatol 2020;72:239-49. [PMID: 31954489 DOI: 10.1016/j.jhep.2019.09.028] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]
110 Xiang X, Wang J, Lu D, Xu X. Targeting tumor-associated macrophages to synergize tumor immunotherapy. Signal Transduct Target Ther 2021;6:75. [PMID: 33619259 DOI: 10.1038/s41392-021-00484-9] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 9.0] [Reference Citation Analysis]
111 Teng D, Ding L, Cai B, Luo Q, Wang H. Interleukin-7 enhances anti-tumor activity of CD8+ T cells in patients with hepatocellular carcinoma. Cytokine 2019;118:115-23. [DOI: 10.1016/j.cyto.2018.04.003] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 3.5] [Reference Citation Analysis]
112 Mohr R, Özdirik B, Lambrecht J, Demir M, Eschrich J, Geisler L, Hellberg T, Loosen SH, Luedde T, Tacke F, Hammerich L, Roderburg C. From Liver Cirrhosis to Cancer: The Role of Micro-RNAs in Hepatocarcinogenesis. Int J Mol Sci 2021;22:1492. [PMID: 33540837 DOI: 10.3390/ijms22031492] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
113 Kang JH, Li MJ, Luan PP, Jiang DK, Chen YW, Xu X, Yu Q, Xu YW, Su Q, Peng WH, Jian WX. NLRC3 silencing accelerates the invasion of hepatocellular carcinoma cell via IL-6/JAK2/STAT3 pathway activation. Cell Biol Int 2020;44:2053-64. [PMID: 32584509 DOI: 10.1002/cbin.11414] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
114 Bartneck M, Schrammen PL, Möckel D, Govaere O, Liepelt A, Krenkel O, Ergen C, McCain MV, Eulberg D, Luedde T, Trautwein C, Kiessling F, Reeves H, Lammers T, Tacke F. The CCR2+ Macrophage Subset Promotes Pathogenic Angiogenesis for Tumor Vascularization in Fibrotic Livers. Cell Mol Gastroenterol Hepatol 2019;7:371-90. [PMID: 30704985 DOI: 10.1016/j.jcmgh.2018.10.007] [Cited by in Crossref: 29] [Cited by in F6Publishing: 28] [Article Influence: 9.7] [Reference Citation Analysis]
115 Lee JH, Mohan CD, Shanmugam MK, Rangappa S, Sethi G, Siveen KS, Chinnathambi A, Alahmadi TA, Alharbi SA, Basappa S, Rangappa KS, Ahn KS. Vitexin abrogates invasion and survival of hepatocellular carcinoma cells through targeting STAT3 signaling pathway. Biochimie 2020;175:58-68. [PMID: 32445654 DOI: 10.1016/j.biochi.2020.05.006] [Cited by in Crossref: 18] [Cited by in F6Publishing: 14] [Article Influence: 18.0] [Reference Citation Analysis]
116 Saviano A, Roehlen N, Virzì A, Roca Suarez AA, Hoshida Y, Lupberger J, Baumert TF. Stromal and Immune Drivers of Hepatocarcinogenesis. In: Hoshida Y, editor. Hepatocellular Carcinoma. Cham: Springer International Publishing; 2019. pp. 317-31. [DOI: 10.1007/978-3-030-21540-8_15] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
117 Xiao H, Wang B, Xiong HX, Guan JF, Wang J, Tan T, Lin K, Zou SB, Hu ZG, Wang K. A novel prognostic index of hepatocellular carcinoma based on immunogenomic landscape analysis. J Cell Physiol 2021;236:2572-91. [PMID: 32853412 DOI: 10.1002/jcp.30015] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
118 Zhao B, Wang Y, Tan X, Ke K, Zheng X, Wang F, Lan S, Liao N, Cai Z, Shi Y, Zheng Y, Lai Y, Wang L, Li Q, Liu J, Huang A, Liu X. Inflammatory Micro-environment Contributes to Stemness Properties and Metastatic Potential of HCC via the NF-κB/miR-497/SALL4 Axis. Mol Ther Oncolytics 2019;15:79-90. [PMID: 31650028 DOI: 10.1016/j.omto.2019.08.009] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 5.5] [Reference Citation Analysis]
119 Peiseler M, Tacke F. Inflammatory Mechanisms Underlying Nonalcoholic Steatohepatitis and the Transition to Hepatocellular Carcinoma. Cancers (Basel) 2021;13:730. [PMID: 33578800 DOI: 10.3390/cancers13040730] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
120 Ren C, Ren X, Cao D, Zhao H, Zhai Z, Li H, Li Y, Fu X, He J, Zhao H. CNOT7 depletion reverses natural killer cell resistance by modulating the tumor immune microenvironment of hepatocellular carcinoma. FEBS Open Bio 2020;10:847-60. [PMID: 32160402 DOI: 10.1002/2211-5463.12836] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
121 Zhao J, Li H, Zhao S, Wang E, Zhu J, Feng D, Zhu Y, Dou W, Fan Q, Hu J, Jia L, Liu L. Epigenetic silencing of miR-144/451a cluster contributes to HCC progression via paracrine HGF/MIF-mediated TAM remodeling. Mol Cancer 2021;20:46. [PMID: 33658044 DOI: 10.1186/s12943-021-01343-5] [Reference Citation Analysis]
122 He Q, He X, Deng B, Shi C, Lin L, Liu P, Yang Z, Yang S, Xu Z. Sorafenib and indocyanine green co-loaded in photothermally sensitive liposomes for diagnosis and treatment of advanced hepatocellular carcinoma. J Mater Chem B 2018;6:5823-34. [PMID: 32254989 DOI: 10.1039/c8tb01641k] [Cited by in Crossref: 8] [Cited by in F6Publishing: 1] [Article Influence: 2.7] [Reference Citation Analysis]
123 Chen Y, Wang X, Deng X, Zhang Y, Liao R, Li Y, Yang H, Chen K. DNA Damage Repair Status Predicts Opposite Clinical Prognosis Immunotherapy and Non-Immunotherapy in Hepatocellular Carcinoma. Front Immunol 2021;12:676922. [PMID: 34335575 DOI: 10.3389/fimmu.2021.676922] [Reference Citation Analysis]
124 Zheng Q, Yang Q, Zhou J, Gu X, Zhou H, Dong X, Zhu H, Chen Z. Immune signature-based hepatocellular carcinoma subtypes may provide novel insights into therapy and prognosis predictions. Cancer Cell Int 2021;21:330. [PMID: 34193146 DOI: 10.1186/s12935-021-02033-4] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
125 Bachmann M, Lamprecht L, Gonther S, Pfeilschifter J, Mühl H. A murine cellular model of necroinflammation displays RAGE-dependent cytokine induction that connects to hepatoma cell injury. J Cell Mol Med 2020;24:10356-66. [PMID: 32697038 DOI: 10.1111/jcmm.15649] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
126 Hu X, Bao M, Huang J, Zhou L, Zheng S. Identification and Validation of Novel Biomarkers for Diagnosis and Prognosis of Hepatocellular Carcinoma. Front Oncol 2020;10:541479. [PMID: 33102213 DOI: 10.3389/fonc.2020.541479] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 6.0] [Reference Citation Analysis]
127 Meng J, Gu F, Fang H, Qu B. Elevated Serum S100A9 Indicated Poor Prognosis in Hepatocellular Carcinoma after Curative Resection. J Cancer 2019;10:408-15. [PMID: 30719134 DOI: 10.7150/jca.28409] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
128 Granito A, Muratori L, Lalanne C, Quarneti C, Ferri S, Guidi M, Lenzi M, Muratori P. Hepatocellular carcinoma in viral and autoimmune liver diseases: Role of CD4+ CD25+ Foxp3+ regulatory T cells in the immune microenvironment. World J Gastroenterol 2021;27:2994-3009. [PMID: 34168403 DOI: 10.3748/wjg.v27.i22.2994] [Cited by in CrossRef: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
129 Seewaldt VL. Aspirin and Chemoprevention-Have We Arrived? JAMA Oncol 2018;4:1668-9. [PMID: 30286216 DOI: 10.1001/jamaoncol.2018.4138] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 2.5] [Reference Citation Analysis]
130 Peng S, Chen Y, Gong Y, Li Z, Xie R, Lin Y, Zou B, Li J, Zeng L. Predictive value of intratumour inflammatory cytokine mRNA levels of hepatocellular carcinoma patients and activation of two distinct pathways govern IL-8 induced epithelial-mesenchymal transition in human hepatic cancer cell lines. Cytokine 2019;119:81-9. [PMID: 30903867 DOI: 10.1016/j.cyto.2019.03.012] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 2.5] [Reference Citation Analysis]
131 Li Y, Wei J, Wei Y, Cheng L, Guo B, Meng F, Li F, Zhong Z. Apolipoprotein E Peptide-Guided Disulfide-Cross-Linked Micelles for Targeted Delivery of Sorafenib to Hepatocellular Carcinoma. Biomacromolecules 2020;21:716-24. [DOI: 10.1021/acs.biomac.9b01419] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
132 Wu M, Yang S, Feng X, Li C, Liu X, Zhang Z, Xiao Y, Liu C, Dong J. Combining Preoperative and Postoperative Inflammatory Indicators Can Better Predict the Recurrence of Hepatocellular Carcinoma After Partial Hepatectomy. J Inflamm Res 2021;14:3231-45. [PMID: 34285546 DOI: 10.2147/JIR.S316177] [Reference Citation Analysis]
133 Namineni S, O'Connor T, Faure-Dupuy S, Johansen P, Riedl T, Liu K, Xu H, Singh I, Shinde P, Li F, Pandyra A, Sharma P, Ringelhan M, Muschaweckh A, Borst K, Blank P, Lampl S, Neuhaus K, Durantel D, Farhat R, Weber A, Lenggenhager D, Kündig TM, Staeheli P, Protzer U, Wohlleber D, Holzmann B, Binder M, Breuhahn K, Assmus LM, Nattermann J, Abdullah Z, Rolland M, Dejardin E, Lang PA, Lang KS, Karin M, Lucifora J, Kalinke U, Knolle PA, Heikenwalder M. A dual role for hepatocyte-intrinsic canonical NF-κB signaling in virus control. J Hepatol 2020;72:960-75. [PMID: 31954207 DOI: 10.1016/j.jhep.2019.12.019] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 5.0] [Reference Citation Analysis]
134 He Q, Liu M, Huang W, Chen X, Zhang B, Zhang T, Wang Y, Liu D, Xie M, Ji X, Sun M, Tian D, Xia L. IL-1β-Induced Elevation of Solute Carrier Family 7 Member 11 Promotes Hepatocellular Carcinoma Metastasis Through Up-regulating Programmed Death Ligand 1 and Colony-Stimulating Factor 1. Hepatology 2021. [PMID: 34288020 DOI: 10.1002/hep.32062] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
135 Li T, Zhang X, Lv Z, Gao L, Yan H. Increased Expression of Myeloid-Derived Suppressor Cells in Patients with HBV-Related Hepatocellular Carcinoma. Biomed Res Int 2020;2020:6527192. [PMID: 32258134 DOI: 10.1155/2020/6527192] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
136 Zhang Q, Lou Y, Bai XL, Liang TB. Immunometabolism: A novel perspective of liver cancer microenvironment and its influence on tumor progression. World J Gastroenterol 2018;24:3500-12. [PMID: 30131656 DOI: 10.3748/wjg.v24.i31.3500] [Cited by in CrossRef: 23] [Cited by in F6Publishing: 19] [Article Influence: 7.7] [Reference Citation Analysis]
137 Rennert C, Tauber C, Fehrenbach P, Heim K, Bettinger D, Sogukpinar Ö, Schuch A, Zecher BF, Bengsch B, Lang SA, Bronsert P, Björkström NK, Fichtner-Feigl S, Schultheiss M, Thimme R, Hofmann M. Adaptive Subsets Limit the Anti-Tumoral NK-Cell Activity in Hepatocellular Carcinoma. Cells 2021;10:1369. [PMID: 34199483 DOI: 10.3390/cells10061369] [Reference Citation Analysis]
138 Mantovani S, Varchetta S, Mele D, Donadon M, Torzilli G, Soldani C, Franceschini B, Porta C, Chiellino S, Pedrazzoli P, Santambrogio R, Barabino M, Cigala C, Piccolo G, Opocher E, Maestri M, Sangiovanni A, Bernuzzi S, Lhospice F, Kraiem M, Mondelli MU, Oliviero B. An Anti-MICA/B Antibody and IL-15 Rescue Altered NKG2D-Dependent NK Cell Responses in Hepatocellular Carcinoma. Cancers (Basel) 2020;12:E3583. [PMID: 33266137 DOI: 10.3390/cancers12123583] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
139 Sutti S, Albano E. Adaptive immunity: an emerging player in the progression of NAFLD. Nat Rev Gastroenterol Hepatol 2020;17:81-92. [PMID: 31605031 DOI: 10.1038/s41575-019-0210-2] [Cited by in Crossref: 51] [Cited by in F6Publishing: 42] [Article Influence: 25.5] [Reference Citation Analysis]
140 Yang L, Si H, Ma M, Fang Y, Jiang Y, Wang J, Zhang C, Xiao H. LINC00221 silencing prevents the progression of hepatocellular carcinoma through let-7a-5p-targeted inhibition of MMP11. Cancer Cell Int 2021;21:202. [PMID: 33836753 DOI: 10.1186/s12935-021-01819-w] [Reference Citation Analysis]
141 Qiu LW, Liu YF, Cao XQ, Wang Y, Cui XH, Ye X, Huang SW, Xie HJ, Zhang HJ. Annexin A2 promotion of hepatocellular carcinoma tumorigenesis via the immune microenvironment. World J Gastroenterol 2020;26:2126-37. [PMID: 32476780 DOI: 10.3748/wjg.v26.i18.2126] [Cited by in CrossRef: 6] [Cited by in F6Publishing: 5] [Article Influence: 6.0] [Reference Citation Analysis]
142 Palma E, Doornebal EJ, Chokshi S. Precision-cut liver slices: a versatile tool to advance liver research. Hepatol Int. 2019;13:51-57. [PMID: 30515676 DOI: 10.1007/s12072-018-9913-7] [Cited by in Crossref: 32] [Cited by in F6Publishing: 28] [Article Influence: 10.7] [Reference Citation Analysis]
143 Liu L, Dai B, Li R, Liu Z, Zhang Z. Intravital molecular imaging reveals the restrained capacity of CTLs in the killing of tumor cells in the liver. Theranostics 2021;11:194-208. [PMID: 33391470 DOI: 10.7150/thno.44979] [Reference Citation Analysis]
144 Tan HY, Wang N, Zhang C, Chan YT, Yuen MF, Feng Y. Lysyl Oxidase-Like 4 Fosters an Immunosuppressive Microenvironment During Hepatocarcinogenesis. Hepatology 2021;73:2326-41. [PMID: 33068461 DOI: 10.1002/hep.31600] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
145 Chen M, Xu M, Zhu C, Wang H, Zhao Q, Zhou F. Sirtuin2 enhances the tumoricidal function of liver natural killer cells in a mouse hepatocellular carcinoma model. Cancer Immunol Immunother 2019;68:961-71. [DOI: 10.1007/s00262-019-02337-5] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
146 Zhu J, Yin T, Xu Y, Lu XJ. Therapeutics for advanced hepatocellular carcinoma: Recent advances, current dilemma, and future directions. J Cell Physiol. 2019;234:12122-12132. [PMID: 30644100 DOI: 10.1002/jcp.28048] [Cited by in Crossref: 20] [Cited by in F6Publishing: 21] [Article Influence: 10.0] [Reference Citation Analysis]
147 Zhang X, Yi FS, Shi HZ. Predicting Survival for Patients with Malignant Pleural Effusion: Development of the CONCH Prognostic Model. Cancer Manag Res 2021;13:4699-707. [PMID: 34163245 DOI: 10.2147/CMAR.S305223] [Reference Citation Analysis]
148 Cano L, Cerapio JP, Ruiz E, Marchio A, Turlin B, Casavilca S, Taxa L, Marti G, Deharo E, Pineau P, Bertani S. Liver clear cell foci and viral infection are associated with non-cirrhotic, non-fibrolamellar hepatocellular carcinoma in young patients from South America. Sci Rep 2018;8:9945. [PMID: 30061721 DOI: 10.1038/s41598-018-28286-0] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
149 Du Y, Ma Y, Zhu Q, Liu T, Jiao Y, Yuan P, Wang X. An m6A-Related Prognostic Biomarker Associated With the Hepatocellular Carcinoma Immune Microenvironment. Front Pharmacol 2021;12:707930. [PMID: 34248650 DOI: 10.3389/fphar.2021.707930] [Reference Citation Analysis]
150 Singh P, Toom S, Avula A, Kumar V, Rahma OE. The Immune Modulation Effect of Locoregional Therapies and Its Potential Synergy with Immunotherapy in Hepatocellular Carcinoma. J Hepatocell Carcinoma. 2020;7:11-17. [PMID: 32104669 DOI: 10.2147/jhc.s187121] [Cited by in Crossref: 12] [Cited by in F6Publishing: 7] [Article Influence: 12.0] [Reference Citation Analysis]
151 Feng GS, Hanley KL, Liang Y, Lin X. Improving the Efficacy of Liver Cancer Immunotherapy: The Power of Combined Preclinical and Clinical Studies. Hepatology 2021;73 Suppl 1:104-14. [PMID: 32715491 DOI: 10.1002/hep.31479] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 10.0] [Reference Citation Analysis]
152 Dal Bo M, De Mattia E, Baboci L, Mezzalira S, Cecchin E, Assaraf YG, Toffoli G. New insights into the pharmacological, immunological, and CAR-T-cell approaches in the treatment of hepatocellular carcinoma. Drug Resistance Updates 2020;51:100702. [DOI: 10.1016/j.drup.2020.100702] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 13.0] [Reference Citation Analysis]
153 Shen B, Tong Y, Li Z, Yan H, Ye F, Wang Y, XCai X. C1GALT1C1/COSMC is a novel prognostic biomarker for hepatocellular carcinoma. Clin Res Hepatol Gastroenterol 2020;44:310-20. [PMID: 31471227 DOI: 10.1016/j.clinre.2019.07.017] [Reference Citation Analysis]
154 Gupta M, Akhtar J, Sarwat M. MicroRNAs: Regulators of immunological reactions in hepatocellular carcinoma. Semin Cell Dev Biol 2021:S1084-9521(21)00134-8. [PMID: 34049801 DOI: 10.1016/j.semcdb.2021.05.025] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
155 Du ZQ, Zhao JZ, Dong J, Bi JB, Ren YF, Zhang J, Khalid B, Wu Z, Lv Y, Zhang XF, Wu RQ. Effect of low-dose aspirin administration on long-term survival of cirrhotic patients after splenectomy: A retrospective single-center study. World J Gastroenterol 2019;25:3798-807. [PMID: 31391774 DOI: 10.3748/wjg.v25.i28.3798] [Cited by in CrossRef: 7] [Cited by in F6Publishing: 7] [Article Influence: 7.0] [Reference Citation Analysis]
156 Wu Y, Zhang X, Shen R, Huang J, Lu X, Zheng G, Chen X. Expression and significance of ETFDH in hepatocellular carcinoma. Pathol Res Pract 2019;215:152702. [PMID: 31704152 DOI: 10.1016/j.prp.2019.152702] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
157 Yang Z, Zi Q, Xu K, Wang C, Chi Q. Development of a macrophages-related 4-gene signature and nomogram for the overall survival prediction of hepatocellular carcinoma based on WGCNA and LASSO algorithm. Int Immunopharmacol 2021;90:107238. [PMID: 33316739 DOI: 10.1016/j.intimp.2020.107238] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
158 Wu C, Lin J, Weng Y, Zeng DN, Xu J, Luo S, Xu L, Liu M, Hua Q, Liu CQ, Li JQ, Liao J, Sun C, Zhou J, Chen MS, Liu C, Guo Z, Zhuang SM, Huang JH, Zheng L. Myeloid signature reveals immune contexture and predicts the prognosis of hepatocellular carcinoma. J Clin Invest 2020;130:4679-93. [PMID: 32497024 DOI: 10.1172/JCI135048] [Cited by in Crossref: 8] [Cited by in F6Publishing: 3] [Article Influence: 8.0] [Reference Citation Analysis]
159 Malehmir M, Pfister D, Gallage S, Szydlowska M, Inverso D, Kotsiliti E, Leone V, Peiseler M, Surewaard BGJ, Rath D, Ali A, Wolf MJ, Drescher H, Healy ME, Dauch D, Kroy D, Krenkel O, Kohlhepp M, Engleitner T, Olkus A, Sijmonsma T, Volz J, Deppermann C, Stegner D, Helbling P, Nombela-arrieta C, Rafiei A, Hinterleitner M, Rall M, Baku F, Borst O, Wilson CL, Leslie J, O’connor T, Weston CJ, Adams DH, Sheriff L, Teijeiro A, Prinz M, Bogeska R, Anstee N, Bongers MN, Notohamiprodjo M, Geisler T, Withers DJ, Ware J, Mann DA, Augustin HG, Vegiopoulos A, Milsom MD, Rose AJ, Lalor PF, Llovet JM, Pinyol R, Tacke F, Rad R, Matter M, Djouder N, Kubes P, Knolle PA, Unger K, Zender L, Nieswandt B, Gawaz M, Weber A, Heikenwalder M. Platelet GPIbα is a mediator and potential interventional target for NASH and subsequent liver cancer. Nat Med 2019;25:641-55. [DOI: 10.1038/s41591-019-0379-5] [Cited by in Crossref: 83] [Cited by in F6Publishing: 67] [Article Influence: 41.5] [Reference Citation Analysis]
160 Liu ZL, Liu JH, Staiculescu D, Chen J. Combination of molecularly targeted therapies and immune checkpoint inhibitors in the new era of unresectable hepatocellular carcinoma treatment. Ther Adv Med Oncol 2021;13:17588359211018026. [PMID: 34104226 DOI: 10.1177/17588359211018026] [Reference Citation Analysis]
161 Xie C, Li SY, Fang JH, Zhu Y, Yang JE. Functional long non-coding RNAs in hepatocellular carcinoma. Cancer Lett 2021;500:281-91. [PMID: 33129957 DOI: 10.1016/j.canlet.2020.10.042] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
162 Zhou J, Chen J, Wei Q, Saeb-Parsy K, Xu X. The Role of Ischemia/Reperfusion Injury in Early Hepatic Allograft Dysfunction. Liver Transpl 2020;26:1034-48. [PMID: 32294292 DOI: 10.1002/lt.25779] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
163 Sircana A, Paschetta E, Saba F, Molinaro F, Musso G. Recent Insight into the Role of Fibrosis in Nonalcoholic Steatohepatitis-Related Hepatocellular Carcinoma. Int J Mol Sci 2019;20:E1745. [PMID: 30970564 DOI: 10.3390/ijms20071745] [Cited by in Crossref: 20] [Cited by in F6Publishing: 15] [Article Influence: 10.0] [Reference Citation Analysis]
164 Macek Jilkova Z, Aspord C, Kurma K, Granon A, Sengel C, Sturm N, Marche PN, Decaens T. Immunologic Features of Patients With Advanced Hepatocellular Carcinoma Before and During Sorafenib or Anti-programmed Death-1/Programmed Death-L1 Treatment. Clin Transl Gastroenterol 2019;10:e00058. [PMID: 31295151 DOI: 10.14309/ctg.0000000000000058] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 14.0] [Reference Citation Analysis]
165 Peng Y, Wong CC, Yu J. The paradox of immunotherapy in NASH-HCC. Signal Transduct Target Ther 2021;6:228. [PMID: 34112767 DOI: 10.1038/s41392-021-00654-9] [Reference Citation Analysis]
166 Chen DP, Ning WR, Jiang ZZ, Peng ZP, Zhu LY, Zhuang SM, Kuang DM, Zheng L, Wu Y. Glycolytic activation of peritumoral monocytes fosters immune privilege via the PFKFB3-PD-L1 axis in human hepatocellular carcinoma. J Hepatol. 2019;71:333-343. [PMID: 31071366 DOI: 10.1016/j.jhep.2019.04.007] [Cited by in Crossref: 28] [Cited by in F6Publishing: 28] [Article Influence: 14.0] [Reference Citation Analysis]
167 Wang Q, Yu CR. Association between liver targeted antiviral therapy in colorectal cancer and survival benefits: An appraisal. World J Clin Cases 2020;8:2111-5. [PMID: 32548140 DOI: 10.12998/wjcc.v8.i11.2111] [Cited by in CrossRef: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
168 Atorrasagasti C, Piccioni F, Borowski S, Tirado-González I, Freitag N, Cantero MJ, Bayo J, Mazzolini G, Alaniz LD, Blois SM, Garcia MG. Acceleration of TAA-Induced Liver Fibrosis by Stress Exposure Is Associated with Upregulation of Nerve Growth Factor and Glycopattern Deviations. Int J Mol Sci 2021;22:5055. [PMID: 34064584 DOI: 10.3390/ijms22105055] [Reference Citation Analysis]
169 Leone V, Ali A, Weber A, Tschaharganeh DF, Heikenwalder M. Liver Inflammation and Hepatobiliary Cancers. Trends Cancer 2021;7:606-23. [PMID: 33674229 DOI: 10.1016/j.trecan.2021.01.012] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
170 Mohr R, Jost-Brinkmann F, Özdirik B, Lambrecht J, Hammerich L, Loosen SH, Luedde T, Demir M, Tacke F, Roderburg C. Lessons From Immune Checkpoint Inhibitor Trials in Hepatocellular Carcinoma. Front Immunol 2021;12:652172. [PMID: 33859646 DOI: 10.3389/fimmu.2021.652172] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
171 Weng J, Atyah M, Zhou C, Ren N. Prospects and challenges of circulating tumor DNA in precision medicine of hepatocellular carcinoma. Clin Exp Med 2020;20:329-37. [PMID: 32239299 DOI: 10.1007/s10238-020-00620-9] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 8.0] [Reference Citation Analysis]
172 Shao J, Li S, Liu Y, Zheng M. Extracellular vesicles participate in macrophage-involved immune responses under liver diseases. Life Sci 2020;240:117094. [PMID: 31760101 DOI: 10.1016/j.lfs.2019.117094] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
173 Mukaida N, Nakamoto Y. Emergence of immunotherapy as a novel way to treat hepatocellular carcinoma. World J Gastroenterol. 2018;24:1839-1858. [PMID: 29740200 DOI: 10.3748/wjg.v24.i17.1839] [Cited by in CrossRef: 15] [Cited by in F6Publishing: 19] [Article Influence: 5.0] [Reference Citation Analysis]
174 Wu Y, Min J, Ge C, Shu J, Tian D, Yuan Y, Zhou D. Interleukin 22 in Liver Injury, Inflammation and Cancer. Int J Biol Sci 2020;16:2405-13. [PMID: 32760208 DOI: 10.7150/ijbs.38925] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 6.0] [Reference Citation Analysis]
175 Chen W, Zhang X, Bi K, Zhou H, Xu J, Dai Y, Diao H. Comprehensive Study of Tumor Immune Microenvironment and Relevant Genes in Hepatocellular Carcinoma Identifies Potential Prognostic Significance. Front Oncol 2020;10:554165. [PMID: 33072579 DOI: 10.3389/fonc.2020.554165] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
176 Shi R, Gao S, Zhang J, Xu J, Graham LM, Yang X, Li C. Collagen prolyl 4-hydroxylases modify tumor progression. Acta Biochim Biophys Sin (Shanghai) 2021;53:805-14. [PMID: 34009234 DOI: 10.1093/abbs/gmab065] [Reference Citation Analysis]
177 Llovet JM, Kelley RK, Villanueva A, Singal AG, Pikarsky E, Roayaie S, Lencioni R, Koike K, Zucman-Rossi J, Finn RS. Hepatocellular carcinoma. Nat Rev Dis Primers 2021;7:6. [PMID: 33479224 DOI: 10.1038/s41572-020-00240-3] [Cited by in Crossref: 96] [Cited by in F6Publishing: 62] [Article Influence: 96.0] [Reference Citation Analysis]
178 Na BG, Kim YK, Hwang S, Lee KJ, Park GC, Ahn CS, Kim KH, Moon DB, Ha TY, Song GW, Jung DH, Yang H, Yoon YI, Tak E, Park YH, Lee SG. Absence of association between pretransplant serum soluble programmed death protein-1 level and prognosis following living donor liver transplantation in patients with hepatocellular carcinoma. Medicine (Baltimore) 2021;100:e25640. [PMID: 33907121 DOI: 10.1097/MD.0000000000025640] [Reference Citation Analysis]
179 Li TY, Yang Y, Zhou G, Tu ZK. Immune suppression in chronic hepatitis B infection associated liver disease: A review. World J Gastroenterol. 2019;25:3527-3537. [PMID: 31367154 DOI: 10.3748/wjg.v25.i27.3527] [Cited by in CrossRef: 21] [Cited by in F6Publishing: 18] [Article Influence: 21.0] [Reference Citation Analysis]
180 Rochigneux P, Chanez B, De Rauglaudre B, Mitry E, Chabannon C, Gilabert M. Adoptive Cell Therapy in Hepatocellular Carcinoma: Biological Rationale and First Results in Early Phase Clinical Trials. Cancers (Basel). 2021;13. [PMID: 33450845 DOI: 10.3390/cancers13020271] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
181 Lu X, Xu C, Dong J, Zuo S, Zhang H, Jiang C, Wu J, Wei J. Liraglutide activates nature killer cell-mediated antitumor responses by inhibiting IL-6/STAT3 signaling in hepatocellular carcinoma. Transl Oncol 2021;14:100872. [PMID: 32979685 DOI: 10.1016/j.tranon.2020.100872] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
182 Haberl EM, Pohl R, Rein-Fischboeck L, Feder S, Sinal CJ, Bruckmann A, Hoering M, Krautbauer S, Liebisch G, Buechler C. Overexpression of Hepatocyte Chemerin-156 Lowers Tumor Burden in a Murine Model of Diethylnitrosamine-Induced Hepatocellular Carcinoma. Int J Mol Sci 2019;21:E252. [PMID: 31905933 DOI: 10.3390/ijms21010252] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
183 Ke M, Zhang Z, Xu B, Zhao S, Ding Y, Wu X, Wu R, Lv Y, Dong J. Baicalein and baicalin promote antitumor immunity by suppressing PD-L1 expression in hepatocellular carcinoma cells. Int Immunopharmacol 2019;75:105824. [PMID: 31437792 DOI: 10.1016/j.intimp.2019.105824] [Cited by in Crossref: 31] [Cited by in F6Publishing: 21] [Article Influence: 15.5] [Reference Citation Analysis]
184 Santhakumar C, Gane EJ, Liu K, Mccaughan GW. Current perspectives on the tumor microenvironment in hepatocellular carcinoma. Hepatol Int 2020;14:947-57. [DOI: 10.1007/s12072-020-10104-3] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
185 Zhang J, Chen M, Zhai Y, Fu Y. HOTAIR regulates lipopolysaccharide-induced inflammatory response in hepatocytes. J Cell Physiol 2020;235:4247-55. [PMID: 31621909 DOI: 10.1002/jcp.29301] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
186 Mohan CD, Rangappa S, Nayak SC, Sethi G, Rangappa KS. Paradoxical functions of long noncoding RNAs in modulating STAT3 signaling pathway in hepatocellular carcinoma. Biochim Biophys Acta Rev Cancer 2021;1876:188574. [PMID: 34062154 DOI: 10.1016/j.bbcan.2021.188574] [Reference Citation Analysis]
187 Roderburg C, Wree A, Demir M, Schmelzle M, Tacke F. The role of the innate immune system in the development and treatment of hepatocellular carcinoma. Hepat Oncol 2020;7:HEP17. [PMID: 32273975 DOI: 10.2217/hep-2019-0007] [Cited by in Crossref: 16] [Cited by in F6Publishing: 12] [Article Influence: 16.0] [Reference Citation Analysis]
188 Zou H, Tuhin IJ, Monty MA, Luo S, Shao J, Yan Z, Yu L. Gene Therapy for Hepatocellular Carcinoma Using Adenoviral Vectors Delivering a Gene Encoding IL-17A-Neutralizing Antibody Fragments. Hum Gene Ther 2020;31:1074-85. [PMID: 32390483 DOI: 10.1089/hum.2019.169] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
189 Zhang R, Zhang Z, Liu Z, Wei D, Wu X, Bian H, Chen Z. Adoptive cell transfer therapy for hepatocellular carcinoma. Front Med 2019;13:3-11. [DOI: 10.1007/s11684-019-0684-x] [Cited by in Crossref: 18] [Cited by in F6Publishing: 16] [Article Influence: 9.0] [Reference Citation Analysis]
190 Zhang T, Li H, Wang K, Xu B, Chen ZN, Bian H. Deficiency of CD147 Attenuated Non-alcoholic Steatohepatitis Progression in an NLRP3-Dependent Manner. Front Cell Dev Biol 2020;8:784. [PMID: 32903542 DOI: 10.3389/fcell.2020.00784] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
191 Sung PS, Shin EC. Immunological Mechanisms for Hepatocellular Carcinoma Risk after Direct-Acting Antiviral Treatment of Hepatitis C Virus Infection. J Clin Med 2021;10:E221. [PMID: 33435135 DOI: 10.3390/jcm10020221] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
192 Ocker M, Mayr C, Kiesslich T, Stintzing S, Neureiter D. Immunmodulatory Treatment Strategies of Hepatocellular Carcinoma: From Checkpoint Inhibitors Now to an Integrated Approach in the Future. Cancers (Basel) 2021;13:1558. [PMID: 33805268 DOI: 10.3390/cancers13071558] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
193 Nikolova-Karakashian M. Sphingolipids at the Crossroads of NAFLD and Senescence. Adv Cancer Res 2018;140:155-90. [PMID: 30060808 DOI: 10.1016/bs.acr.2018.05.002] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 3.3] [Reference Citation Analysis]
194 Ji G, Ma L, Yao H, Ma S, Si X, Wang Y, Bao X, Ma L, Chen F, Ma C, Huang L, Fang X, Song W. Precise delivery of obeticholic acid via nanoapproach for triggering natural killer T cell-mediated liver cancer immunotherapy. Acta Pharm Sin B 2020;10:2171-82. [PMID: 33304784 DOI: 10.1016/j.apsb.2020.09.004] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
195 Guan C, He L, Chang Z, Gu X, Liang J, Liu R. ZNF774 is a potent suppressor of hepatocarcinogenesis through dampening the NOTCH2 signaling. Oncogene 2020;39:1665-80. [PMID: 31659254 DOI: 10.1038/s41388-019-1075-0] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
196 Tietze L, Kessler SM. The Good, the Bad, the Question-H19 in Hepatocellular Carcinoma. Cancers (Basel) 2020;12:E1261. [PMID: 32429417 DOI: 10.3390/cancers12051261] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 9.0] [Reference Citation Analysis]
197 Liu X, Ye N, Liu S, Guan J, Deng Q, Zhang Z, Xiao C, Ding ZY, Zhang BX, Chen XP, Li Z, Yang X. Hyperbaric Oxygen Boosts PD-1 Antibody Delivery and T Cell Infiltration for Augmented Immune Responses Against Solid Tumors. Adv Sci (Weinh) 2021;8:e2100233. [PMID: 34085419 DOI: 10.1002/advs.202100233] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
198 Duda DG, Dima SO, Cucu D, Sorop A, Klein S, Ancukiewicz M, Kitahara S, Iacob S, Bacalbasa N, Tomescu D, Herlea V, Tanase C, Croitoru A, Popescu I. Potential Circulating Biomarkers of Recurrence after Hepatic Resection or Liver Transplantation in Hepatocellular Carcinoma Patients. Cancers (Basel) 2020;12:E1275. [PMID: 32443546 DOI: 10.3390/cancers12051275] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
199 Hofmann M, Tauber C, Hensel N, Thimme R. CD8+ T Cell Responses during HCV Infection and HCC. J Clin Med 2021;10:991. [PMID: 33801203 DOI: 10.3390/jcm10050991] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
200 Patel SS, Sandur A, El-Kebir M, Gaba RC, Schook LB, Schachtschneider KM. Transcriptional Profiling of Porcine HCC Xenografts Provides Insights Into Tumor Cell Microenvironment Signaling. Front Genet 2021;12:657330. [PMID: 33995488 DOI: 10.3389/fgene.2021.657330] [Reference Citation Analysis]
201 Barron KA, Jeffries KA, Krupenko NI. Sphingolipids and the link between alcohol and cancer. Chem Biol Interact 2020;322:109058. [PMID: 32171848 DOI: 10.1016/j.cbi.2020.109058] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
202 Shi W, Feng L, Dong S, Ning Z, Hua Y, Liu L, Chen Z, Meng Z. Exploration of prognostic index based on immune-related genes in patients with liver hepatocellular carcinoma. Biosci Rep 2020;40:BSR20194240. [PMID: 32579175 DOI: 10.1042/BSR20194240] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
203 Mao D, Zhang Z, Zhao X, Dong X. Autophagy-related genes prognosis signature as potential predictive markers for immunotherapy in hepatocellular carcinoma. PeerJ 2020;8:e8383. [PMID: 31988807 DOI: 10.7717/peerj.8383] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 12.0] [Reference Citation Analysis]
204 Zhang L, Ding J, Li HY, Wang ZH, Wu J. Immunotherapy for advanced hepatocellular carcinoma, where are we? Biochim Biophys Acta Rev Cancer 2020;1874:188441. [PMID: 33007432 DOI: 10.1016/j.bbcan.2020.188441] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 9.0] [Reference Citation Analysis]
205 Zhang S, Liu Z, Wu D, Chen L, Xie L. Single-Cell RNA-Seq Analysis Reveals Microenvironmental Infiltration of Plasma Cells and Hepatocytic Prognostic Markers in HCC With Cirrhosis. Front Oncol 2020;10:596318. [PMID: 33224891 DOI: 10.3389/fonc.2020.596318] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 6.0] [Reference Citation Analysis]
206 Liepelt A, Wehr A, Kohlhepp M, Mossanen JC, Kreggenwinkel K, Denecke B, Costa IG, Luedde T, Trautwein C, Tacke F. CXCR6 protects from inflammation and fibrosis in NEMOLPC-KO mice. Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease 2019;1865:391-402. [DOI: 10.1016/j.bbadis.2018.11.020] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 4.0] [Reference Citation Analysis]
207 Chen Z, Li S, Shen M, Lu X, Bao C, Chen D, Ding J, Wang Q, Huang S, Cong W, Han L, He X. The Mutational and Transcriptional Landscapes of Hepatocarcinogenesis in a Rat Model. iScience 2020;23:101690. [PMID: 33163943 DOI: 10.1016/j.isci.2020.101690] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
208 He C, Hua W, Liu J, Fan L, Wang H, Sun G. Exosomes derived from endoplasmic reticulum-stressed liver cancer cells enhance the expression of cytokines in macrophages via the STAT3 signaling pathway. Oncol Lett 2020;20:589-600. [PMID: 32565984 DOI: 10.3892/ol.2020.11609] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 8.0] [Reference Citation Analysis]
209 Ko CJ, Li CJ, Wu MY, Chu PY. Overexpression of epithelial cell adhesion molecule as a predictor of poor outcome in patients with hepatocellular carcinoma. Exp Ther Med 2018;16:4810-6. [PMID: 30542436 DOI: 10.3892/etm.2018.6794] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
210 Yuen VW, Wong CC. Hypoxia-inducible factors and innate immunity in liver cancer. J Clin Invest 2020;130:5052-62. [PMID: 32750043 DOI: 10.1172/JCI137553] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 6.0] [Reference Citation Analysis]
211 Dang Y, Chen J, Feng W, Qiao C, Han W, Nie Y, Wu K, Fan D, Xia L. Interleukin 1β-mediated HOXC10 Overexpression Promotes Hepatocellular Carcinoma Metastasis by Upregulating PDPK1 and VASP. Theranostics 2020;10:3833-48. [PMID: 32206125 DOI: 10.7150/thno.41712] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 5.0] [Reference Citation Analysis]
212 Xu Y, Huang Y, Xu W, Zheng X, Yi X, Huang L, Wang Y, Wu K. Activated Hepatic Stellate Cells (HSCs) Exert Immunosuppressive Effects in Hepatocellular Carcinoma by Producing Complement C3. Onco Targets Ther 2020;13:1497-505. [PMID: 32110047 DOI: 10.2147/OTT.S234920] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 10.0] [Reference Citation Analysis]
213 Dai Q, Zhang C, Yuan Z, Sun Q, Jiang Y. Current discovery strategies for hepatocellular carcinoma therapeutics. Expert Opinion on Drug Discovery 2020;15:243-58. [DOI: 10.1080/17460441.2020.1696769] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
214 Wang T, Fu X, Jin T, Zhang L, Liu B, Wu Y, Xu F, Wang X, Ye K, Zhang W, Ye L. Aspirin targets P4HA2 through inhibiting NF-κB and LMCD1-AS1/let-7g to inhibit tumour growth and collagen deposition in hepatocellular carcinoma. EBioMedicine 2019;45:168-80. [PMID: 31278071 DOI: 10.1016/j.ebiom.2019.06.048] [Cited by in Crossref: 29] [Cited by in F6Publishing: 26] [Article Influence: 14.5] [Reference Citation Analysis]
215 El-Ahwany E, Mansy SS, Zoheiry M, Mourad L, Mahmoud S, Abu-Taleb H, Hassanien M, Hassan M. MicroRNA-195 vector influence on the development of gradually induced hepatocellular carcinoma in murine model. Ultrastruct Pathol 2020;44:203-10. [PMID: 32216509 DOI: 10.1080/01913123.2020.1744783] [Reference Citation Analysis]
216 Chen W, Ou M, Tang D, Dai Y, Du W. Identification and Validation of Immune-Related Gene Prognostic Signature for Hepatocellular Carcinoma. J Immunol Res 2020;2020:5494858. [PMID: 32211443 DOI: 10.1155/2020/5494858] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 12.0] [Reference Citation Analysis]
217 Wirtz TH, Brandt EF, Berres ML. Liver DCs in health and disease. Int Rev Cell Mol Biol 2019;348:263-99. [PMID: 31810555 DOI: 10.1016/bs.ircmb.2019.08.001] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
218 Fan J, Li J, Han J, Zhang Y, Gu A, Song F, Duan J, Yin D, Wang L, Yi Y. Expression of leukocyte immunoglobulin-like receptor subfamily B expression on immune cells in hepatocellular carcinoma. Mol Immunol 2021;136:82-97. [PMID: 34098344 DOI: 10.1016/j.molimm.2021.05.011] [Reference Citation Analysis]
219 Li Y, Wang J, Song K, Liu S, Zhang H, Wang F, Ni C, Zhai W, Liang J, Qin Z, Zhang J. S100A4 promotes hepatocellular carcinogenesis by intensifying fibrosis-associated cancer cell stemness. Oncoimmunology 2020;9:1725355. [PMID: 32117590 DOI: 10.1080/2162402X.2020.1725355] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 4.0] [Reference Citation Analysis]
220 Ou DL, Lin YY, Hsu CL, Chen CW, Yu JS, Miaw SC, Hsu PN, Cheng AL, Hsu C. Development of a PD-L1-Expressing Orthotopic Liver Cancer Model: Implications for Immunotherapy for Hepatocellular Carcinoma. Liver Cancer. 2019;8:155-171. [PMID: 31192153 DOI: 10.1159/000489318] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 3.7] [Reference Citation Analysis]
221 Peña-Asensio J, Calvo H, Torralba M, Miquel J, Sanz-de-Villalobos E, Larrubia JR. Anti-PD-1/PD-L1 Based Combination Immunotherapy to Boost Antigen-Specific CD8+ T Cell Response in Hepatocellular Carcinoma. Cancers (Basel) 2021;13:1922. [PMID: 33923463 DOI: 10.3390/cancers13081922] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
222 de Mattos ÂZ, Debes JD, Boonstra A, Yang JD, Balderramo DC, Sartori GDP, de Mattos AA. Current impact of viral hepatitis on liver cancer development: The challenge remains. World J Gastroenterol 2021;27:3556-67. [PMID: 34239269 DOI: 10.3748/wjg.v27.i24.3556] [Reference Citation Analysis]
223 Dyhl-Polk A, Mikkelsen MK, Ladekarl M, Nielsen DL. Clinical Trials of Immune Checkpoint Inhibitors in Hepatocellular Carcinoma. J Clin Med 2021;10:2662. [PMID: 34208788 DOI: 10.3390/jcm10122662] [Reference Citation Analysis]
224 Zhang W, Cai J, Wu B, Shen Z. pH-responsive hyaluronic acid nanoparticles coloaded with sorafenib and cisplatin for treatment of hepatocellular carcinoma. J Biomater Appl 2019;34:219-28. [PMID: 31084233 DOI: 10.1177/0885328219849711] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
225 Zhu M, Jin Z, Hubbard JM. Management of Non-Colorectal Digestive Cancers with Microsatellite Instability. Cancers (Basel) 2021;13:651. [PMID: 33561950 DOI: 10.3390/cancers13040651] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
226 Liu Y, Li J, Liao L, Huang H, Fan S, Fu R, Huang J, Shi C, Yu L, Chen KX, Zhang YY, Luo C, Li GM. Cyclin-dependent kinase inhibitor roscovitine attenuates liver inflammation and fibrosis by influencing initiating steps of liver injury. Clin Sci (Lond) 2021;135:925-41. [PMID: 33786590 DOI: 10.1042/CS20201111] [Reference Citation Analysis]
227 Wang T, Zhang J, Hou T, Yin X, Zhang N. Selective targeting of tumor cells and tumor associated macrophages separately by twin-like core-shell nanoparticles for enhanced tumor-localized chemoimmunotherapy. Nanoscale 2019;11:13934-46. [PMID: 31305839 DOI: 10.1039/c9nr03374b] [Cited by in Crossref: 35] [Cited by in F6Publishing: 17] [Article Influence: 17.5] [Reference Citation Analysis]
228 Sukowati CHC, Cabral LKD, Tiribelli C, Pascut D. Circulating Long and Circular Noncoding RNA as Non-Invasive Diagnostic Tools of Hepatocellular Carcinoma. Biomedicines 2021;9:90. [PMID: 33477833 DOI: 10.3390/biomedicines9010090] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 6.0] [Reference Citation Analysis]
229 Moehler M, Heo J, Lee HC, Tak WY, Chao Y, Paik SW, Yim HJ, Byun KS, Baron A, Ungerechts G, Jonker D, Ruo L, Cho M, Kaubisch A, Wege H, Merle P, Ebert O, Habersetzer F, Blanc JF, Rosmorduc O, Lencioni R, Patt R, Leen AM, Foerster F, Homerin M, Stojkowitz N, Lusky M, Limacher JM, Hennequi M, Gaspar N, McFadden B, De Silva N, Shen D, Pelusio A, Kirn DH, Breitbach CJ, Burke JM. Vaccinia-based oncolytic immunotherapy Pexastimogene Devacirepvec in patients with advanced hepatocellular carcinoma after sorafenib failure: a randomized multicenter Phase IIb trial (TRAVERSE). Oncoimmunology 2019;8:1615817. [PMID: 31413923 DOI: 10.1080/2162402X.2019.1615817] [Cited by in Crossref: 31] [Cited by in F6Publishing: 14] [Article Influence: 15.5] [Reference Citation Analysis]
230 Teng CF, Wang T, Shih FY, Shyu WC, Jeng LB. Therapeutic efficacy of dendritic cell vaccine combined with programmed death 1 inhibitor for hepatocellular carcinoma. J Gastroenterol Hepatol 2021;36:1988-96. [PMID: 33462840 DOI: 10.1111/jgh.15398] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
231 Wen Y, Liu Y, Zhang H, Zou M, Yan D, Chen D, Zhao Y. A responsive porous hydrogel particle-based delivery system for oncotherapy. Nanoscale 2019;11:2687-93. [DOI: 10.1039/c8nr09990a] [Cited by in Crossref: 22] [Cited by in F6Publishing: 3] [Article Influence: 11.0] [Reference Citation Analysis]
232 Tian Z, Hou X, Liu W, Han Z, Wei L. Macrophages and hepatocellular carcinoma.Cell Biosci. 2019;9:79. [PMID: 31572568 DOI: 10.1186/s13578-019-0342-7] [Cited by in Crossref: 18] [Cited by in F6Publishing: 19] [Article Influence: 9.0] [Reference Citation Analysis]
233 Farc O, Cristea V. An overview of the tumor microenvironment, from cells to complex networks (Review). Exp Ther Med 2021;21:96. [PMID: 33363607 DOI: 10.3892/etm.2020.9528] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 6.0] [Reference Citation Analysis]
234 Qiu H, Liu C, Huang M, Shen S, Wang W. Prognostic Value of Combined CA19-9 with Aspartate Aminotransferase to Lymphocyte Ratio in Patients with Intrahepatic Cholangiocarcinoma After Hepatectomy. Cancer Manag Res 2021;13:5969-80. [PMID: 34377017 DOI: 10.2147/CMAR.S320380] [Reference Citation Analysis]
235 Ye Y, Guo J, Xiao P, Ning J, Zhang R, Liu P, Yu W, Xu L, Zhao Y, Yu J. Macrophages-induced long noncoding RNA H19 up-regulation triggers and activates the miR-193b/MAPK1 axis and promotes cell aggressiveness in hepatocellular carcinoma. Cancer Lett 2020;469:310-22. [PMID: 31705929 DOI: 10.1016/j.canlet.2019.11.001] [Cited by in Crossref: 34] [Cited by in F6Publishing: 30] [Article Influence: 17.0] [Reference Citation Analysis]
236 Lin Y, Huang G, Jin H, Jian Z. Circular RNA Gprc5a Promotes HCC Progression by Activating YAP1/TEAD1 Signalling Pathway by Sponging miR-1283. Onco Targets Ther 2020;13:4509-21. [PMID: 32547082 DOI: 10.2147/OTT.S240261] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
237 Chen Y, Hao X, Sun R, Wei H, Tian Z. Natural Killer Cell-Derived Interferon-Gamma Promotes Hepatocellular Carcinoma Through the Epithelial Cell Adhesion Molecule-Epithelial-to-Mesenchymal Transition Axis in Hepatitis B Virus Transgenic Mice. Hepatology 2019;69:1735-50. [PMID: 30329167 DOI: 10.1002/hep.30317] [Cited by in Crossref: 15] [Cited by in F6Publishing: 18] [Article Influence: 7.5] [Reference Citation Analysis]
238 Zhou D, Luan J, Huang C, Li J. Tumor-Associated Macrophages in Hepatocellular Carcinoma: Friend or Foe? Gut Liver 2021;15:500-16. [PMID: 33087588 DOI: 10.5009/gnl20223] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 5.0] [Reference Citation Analysis]
239 Wang S, Ma H, Li X, Mo X, Zhang H, Yang L, Deng Y, Yan Y, Yang G, Liu X, Sun H. DNASE1L3 as an indicator of favorable survival in hepatocellular carcinoma patients following resection. Aging (Albany NY) 2020;12:1171-85. [PMID: 31977318 DOI: 10.18632/aging.102675] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 6.0] [Reference Citation Analysis]
240 Li Z, Zhou Y, Zhang L, Jia K, Wang S, Wang M, Li N, Yu Y, Cao X, Hou J. microRNA-199a-3p inhibits hepatic apoptosis and hepatocarcinogenesis by targeting PDCD4. Oncogenesis 2020;9:95. [PMID: 33099584 DOI: 10.1038/s41389-020-00282-y] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
241 Yu P, Zhang X, Liu N, Tang L, Peng C, Chen X. Pyroptosis: mechanisms and diseases. Signal Transduct Target Ther 2021;6:128. [PMID: 33776057 DOI: 10.1038/s41392-021-00507-5] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 5.0] [Reference Citation Analysis]
242 Casals G, Perramón M, Casals E, Portolés I, Fernández-Varo G, Morales-Ruiz M, Puntes V, Jiménez W. Cerium Oxide Nanoparticles: A New Therapeutic Tool in Liver Diseases. Antioxidants (Basel) 2021;10:660. [PMID: 33923136 DOI: 10.3390/antiox10050660] [Cited by in Crossref: 3] [Article Influence: 3.0] [Reference Citation Analysis]
243 Xu J, Yang X, Zhou Q, Zhuang J, Han S. Biological significance of piRNA in liver cancer: a review. Biomarkers 2020;25:436-40. [PMID: 32662667 DOI: 10.1080/1354750X.2020.1794041] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
244 Yang YM, Kim SY, Seki E. Inflammation and Liver Cancer: Molecular Mechanisms and Therapeutic Targets. Semin Liver Dis. 2019;39:26-42. [PMID: 30809789 DOI: 10.1055/s-0038-1676806] [Cited by in Crossref: 56] [Cited by in F6Publishing: 46] [Article Influence: 28.0] [Reference Citation Analysis]
245 Bartneck M, Koppe C, Fech V, Warzecha KT, Kohlhepp M, Huss S, Weiskirchen R, Trautwein C, Luedde T, Tacke F. Roles of CCR2 and CCR5 for Hepatic Macrophage Polarization in Mice With Liver Parenchymal Cell-Specific NEMO Deletion. Cell Mol Gastroenterol Hepatol 2021;11:327-47. [PMID: 32896623 DOI: 10.1016/j.jcmgh.2020.08.012] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
246 Ersan V, Barut B, Yilmaz S. The Timing of Liver Transplantation Following Downstaging: Wait of Not to Wait? J Gastrointest Cancer 2020;51:1152-6. [PMID: 32856230 DOI: 10.1007/s12029-020-00491-z] [Reference Citation Analysis]
247 Ružić M, Pellicano R, Fabri M, Luzza F, Boccuto L, Brkić S, Abenavoli L. Hepatitis C virus-induced hepatocellular carcinoma: a narrative review. Panminerva Med 2018;60:185-91. [PMID: 29856183 DOI: 10.23736/S0031-0808.18.03472-9] [Cited by in Crossref: 21] [Cited by in F6Publishing: 8] [Article Influence: 7.0] [Reference Citation Analysis]
248 Todoric J, Karin M. The Fire within: Cell-Autonomous Mechanisms in Inflammation-Driven Cancer. Cancer Cell 2019;35:714-20. [PMID: 31085174 DOI: 10.1016/j.ccell.2019.04.001] [Cited by in Crossref: 23] [Cited by in F6Publishing: 17] [Article Influence: 23.0] [Reference Citation Analysis]
249 Liu K, Wang FS, Xu R. Neutrophils in liver diseases: pathogenesis and therapeutic targets. Cell Mol Immunol 2021;18:38-44. [PMID: 33159158 DOI: 10.1038/s41423-020-00560-0] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]
250 Deng G, Yao L, Zeng F, Xiao L, Wang Z. Nomogram For Preoperative Prediction Of Microvascular Invasion Risk In Hepatocellular Carcinoma. Cancer Manag Res. 2019;11:9037-9045. [PMID: 31695495 DOI: 10.2147/cmar.s216178] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 4.0] [Reference Citation Analysis]
251 Chen Q, Chen J, He M, Bai Y, Yan H, Zeng N, Liu F, Wen S, Song L, Sheng Z, Liu C, Fang C. Novel small molecular dye-loaded lipid nanoparticles with efficient near-infrared-II absorption for photoacoustic imaging and photothermal therapy of hepatocellular carcinoma. Biomater Sci 2019;7:3165-77. [DOI: 10.1039/c9bm00528e] [Cited by in Crossref: 20] [Cited by in F6Publishing: 3] [Article Influence: 10.0] [Reference Citation Analysis]
252 Lindblad KE, Lujambio A. Liver metastases inhibit immunotherapy efficacy. Nat Med 2021;27:25-7. [PMID: 33442002 DOI: 10.1038/s41591-020-01190-9] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
253 Yang Z, Zhu H, Zhang L, Wei Q, Zhou L, Xu X, Song P, Liu J, Xie H, Zheng S. DNA methylation of SOCS1/2/3 predicts hepatocellular carcinoma recurrence after liver transplantation. Mol Biol Rep 2020;47:1773-82. [PMID: 32006198 DOI: 10.1007/s11033-020-05271-3] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
254 Zhao F, Liu A, Gong X, Chen H, Wei J, Chen B, Chen S, Yang R, Fan Y, Mao R. Hypoxia-induced RNASEH2A limits activation of cGAS-STING signaling in HCC and predicts poor prognosis. Tumori 2021;:3008916211026019. [PMID: 34165025 DOI: 10.1177/03008916211026019] [Reference Citation Analysis]
255 Deng J, Wei W, Chen Z, Lin B, Zhao W, Luo Y, Zhang X. Engineered Liver-on-a-Chip Platform to Mimic Liver Functions and Its Biomedical Applications: A Review. Micromachines (Basel) 2019;10:E676. [PMID: 31591365 DOI: 10.3390/mi10100676] [Cited by in Crossref: 44] [Cited by in F6Publishing: 31] [Article Influence: 22.0] [Reference Citation Analysis]